184 related articles for article (PubMed ID: 31435963)
1. Clinical relevance of molecular subgrouping of gliomatosis cerebri per 2016 WHO classification: a clinicopathological study of 89 cases.
Kwon MJ; Kang SY; Cho H; Lee JI; Kim ST; Suh YL
Brain Pathol; 2020 Mar; 30(2):235-245. PubMed ID: 31435963
[TBL] [Abstract][Full Text] [Related]
2. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
[TBL] [Abstract][Full Text] [Related]
4. Revisiting prognostic factors of gliomatosis cerebri in adult-type diffuse gliomas.
Shin I; Sim Y; Choi SH; Park YW; Lee N; Ahn SS; Chang JH; Kim SH; Lee SK
J Neurooncol; 2024 Jun; 168(2):239-247. PubMed ID: 38700610
[TBL] [Abstract][Full Text] [Related]
5. Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas.
Broniscer A; Chamdine O; Hwang S; Lin T; Pounds S; Onar-Thomas A; Shurtleff S; Allen S; Gajjar A; Northcott P; Orr BA
Acta Neuropathol; 2016 Feb; 131(2):299-307. PubMed ID: 26744350
[TBL] [Abstract][Full Text] [Related]
6. Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011-2017): a multicenter retrospective study from CGGA.
Zhang K; Liu X; Li G; Chang X; Li S; Chen J; Zhao Z; Wang J; Jiang T; Chai R
Cancer Biol Med; 2022 Nov; 19(10):1460-76. PubMed ID: 36350010
[TBL] [Abstract][Full Text] [Related]
7. IDH1 mutation, a genetic alteration associated with adult gliomatosis cerebri.
Narasimhaiah D; Miquel C; Verhamme E; Desclée P; Cosnard G; Godfraind C
Neuropathology; 2012 Feb; 32(1):30-7. PubMed ID: 21481010
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and radiological features of glioblastoma, IDH-wildtype, grade 4 with histologically lower-grade gliomas.
Motomura K; Kibe Y; Ohka F; Aoki K; Yamaguchi J; Saito R
Brain Tumor Pathol; 2023 Apr; 40(2):48-55. PubMed ID: 36988764
[TBL] [Abstract][Full Text] [Related]
9. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
10. Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes.
Seiz M; Tuettenberg J; Meyer J; Essig M; Schmieder K; Mawrin C; von Deimling A; Hartmann C
Acta Neuropathol; 2010 Aug; 120(2):261-7. PubMed ID: 20514489
[TBL] [Abstract][Full Text] [Related]
11. Imaging features of localized IDH wild-type histologically diffuse astrocytomas: a single-institution case series.
Kibe Y; Motomura K; Ohka F; Aoki K; Shimizu H; Yamaguchi J; Nishikawa T; Saito R
Sci Rep; 2023 Jan; 13(1):23. PubMed ID: 36646712
[TBL] [Abstract][Full Text] [Related]
12. Mutated IDH1 is a favorable prognostic factor for type 2 gliomatosis cerebri.
Kwon MJ; Kim ST; Kwon MJ; Kong DS; Lee D; Park S; Kang SY; Song JY; Nam DH; Kato Y; Choi YL; Suh YL
Brain Pathol; 2012 May; 22(3):307-17. PubMed ID: 21929658
[TBL] [Abstract][Full Text] [Related]
13. Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study.
Ly KI; Oakley DH; Pine AB; Frosch MP; Chiou SH; Betensky RA; Pomerantz SR; Hochberg FH; Batchelor TT; Cahill DP; Dietrich J
Oncologist; 2019 Mar; 24(3):402-413. PubMed ID: 30097523
[TBL] [Abstract][Full Text] [Related]
14. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
15. Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.
Hinrichs BH; Newman S; Appin CL; Dunn W; Cooper L; Pauly R; Kowalski J; Rossi MR; Brat DJ
Acta Neuropathol Commun; 2016 Jan; 4():4. PubMed ID: 26757882
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
17. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
18. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.
Reuss DE; Kratz A; Sahm F; Capper D; Schrimpf D; Koelsche C; Hovestadt V; Bewerunge-Hudler M; Jones DT; Schittenhelm J; Mittelbronn M; Rushing E; Simon M; Westphal M; Unterberg A; Platten M; Paulus W; Reifenberger G; Tonn JC; Aldape K; Pfister SM; Korshunov A; Weller M; Herold-Mende C; Wick W; Brandner S; von Deimling A
Acta Neuropathol; 2015 Sep; 130(3):407-17. PubMed ID: 26087904
[TBL] [Abstract][Full Text] [Related]
19. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma.
Stichel D; Ebrahimi A; Reuss D; Schrimpf D; Ono T; Shirahata M; Reifenberger G; Weller M; Hänggi D; Wick W; Herold-Mende C; Westphal M; Brandner S; Pfister SM; Capper D; Sahm F; von Deimling A
Acta Neuropathol; 2018 Nov; 136(5):793-803. PubMed ID: 30187121
[TBL] [Abstract][Full Text] [Related]
20. Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations.
Izquierdo C; Barritault M; Poncet D; Cartalat S; Joubert B; Bruna J; Jouanneau E; Guyotat J; Vasiljevic A; Fenouil T; Berthezène Y; Honnorat J; Meyronet D; Ducray F
Neurosurgery; 2019 Sep; 85(3):E448-E456. PubMed ID: 30407589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
